the-infoshop.com - The vertical markets research portal
View CartView Cart
Global Information, Inc.
US: +1-860-674-8796
EU: +32-2-535-7543
SG: +65-6223-2436
  Home | Catalog | E-mail Alert | Custom Research | About The Infoshop | Contact Us | Site Map |

* View All Categories
Japanese Korean Chinese

[Report]

Commercial Insight: Transplantation

Published: 2006/06

Contact 24 hrs/day
Table of Contents

Abstract

Overview

Introduction

In 2005, over 50.000 solid organ transplants were conducted in the seven major markets. In order to prevent the patient's immune system from rejecting the transplanted organ, immunosuppression therapy is required for the lifetime of the graft with a base maintenance drug (either Calcineurin- or mTOR inhibitors) and adjunctive therapies (antimetabolites, steroids).

Scope

  • The report focuses on current and future therapies used for immunosuppression in solid organ transplantation, with sales and volume forecasts to 2015
  • Assessment of current and future dynamics, opportunities and threats for immunosuppressants across the seven major markets
  • Overview of organ supply, national donation rates, waiting lists and forecasts of the number of transplants and maintenance population to 2015
  • Assessment of key factors affecting prescription choice, including analysis of regional differences

Report Highlights

The transplantation market poses unusual challenges to pharmaceutical companies, the most significant one being a lack of donor organs: the waiting list for transplants will continue to grow faster than the number of available organs. Another challenge is the static nature of the market: maintenance regimens of stable patients rarely get changed.

The market for immusuppresssants used in transplantation is set to grow to $4.3 billion by 2015s. Despite changing protocols, the leading drug class by value should continue to be calcineurin inhibitors with a 37% market share, followed by mTOR inhibitors

mTOR inhibitors are expected to be the fastest growing class, driven by Wyeth's Rapamune. Datamonitor foresees the drug to gain a greater role as a primary immunsuppressant despite current tolerability issues. Bristol Myers Squibb's injectable fusion protein belatacept may offer another alternative to calcineurin inhibotrs

Reasons to Purchase

  • Identify and understand the dynamics in immunosuppressive protocols as reflected in opinion leaders' thoughts
  • Quantify the future immunosuppressant market size by volume and value for each of the seven major markets
  • Quantify the future market size based on transplant types, numbers and the maintenance population
Table of Contents

[Report]
Commercial Insight: Transplantation
Published: 2006/06
Published by : Datamonitor Datamonitor

Price:
US $ 15,200.00 PDF by E-mail (Single User License)
>
Product Code : DC41971
Please inform me when related publications are released
InfoWatch

Available 24 Hours a Day
US: 1-860-674-8796 EU: 32-2-535-7543 SG: 65-6223-2436
The vertical markets research portal
© 2008, the-infoshop.com by Global Information, Inc. All rights reserved.